Bausch Health,?Canada, which is part of Bausch Health Companies Inc. (BHC,BHC.TO), and its dermatology division, said that Health Canada has approved the Notice of Compliance for ARAZLO or tazarotene lotion, 0.045%, for the topical treatment of acne vulgaris (common acne) in patients 10 years of age and older.
RAZLO is the third new dermatology treatment from Bausch Health, Canada approved by Health Canada in just over 12 months.
The other approvals were for BRYHALI (halobetasol propionate lotion 0.01% w/w), a high to super-high potency topical corticosteroid indicated for corticosteroid-responsive dermatoses and the topical treatment of plaque psoriasis, and DUOBRII (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene) to treat adults with moderate to severe plaque psoriasis.
All three treatments - ARAZLO, BRYHALI and DUOBRII - are manufactured at Bausch Health's Laval, Quebec, facility for Canada and the United States.
For comments and feedback contact: editorial@rttnews.com
Business News